{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-24-000059","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.460852+00:00","generated_at":"2026-06-03T00:17:34.680868+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M","bullets":["Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).","Net loss narrowed to $2.5M from $29.2M; adjusted EBITDA improved to $10.5M from -$15.1M.","Total test reports +40% to 20,888; TissueCypher +148%, IDgenetix +90%.","FY2024 revenue guidance raised to $255-265M from prior $235-240M.","Cash & marketable securities $239.2M; gross margin 78% (adj. 81%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-24-000059","json":"https://secwatch.observer/filing/0001447362-24-000059.json","markdown":"https://secwatch.observer/filing/0001447362-24-000059.md","text":"https://secwatch.observer/filing/0001447362-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000059/0001447362-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000059/cstl-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:17:34.680868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87f1d29236a5dbb1e4c764da3ce415f6793b7d6c","claim":"CASTLE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $73.0 million, net income Net loss... was $2.5 million. Guidance raised.","evidence_excerpt":"such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $ 255-265 million from $235-240 million Conference call and webcast today at 4:30","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000059/0001447362-24-000059-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$73.0 million"},{"label":"Net income","value":"Net loss... was $2.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}